CD163 and hepatocellular carcinoma: CM from human HCC SNU739 cells or murine Hepa1-6 pre-treated with sorafenib strikingly increased the expression of CD163, CD206, or ARG1, which were the typical markers labeling M2-TAMs as compared with the corresponding control group (Fig. 2A–C, Fig. S5A, B).